Aim To evaluate the predictive value of plasma soluble growth stimulating express gene protein 2 (sST2) concentration for clinical prognosis in 90 days after discharge of patients with acute myocardial infarction (AMI).Methods 112 patients with AMI hospitalized in Xinxiang Central Hospital from January to December 2017 were selected as subjects of study. According to the best cut-off value of receiver operating characteristic curve (ROC) for sST2 concentration predicting major adverse cardiovascular event (MACE), the subjects were divided into high sST2 group and low sST2 group. The clinical data and the incidence of MACE (defined as death and new onset of chronic heart failure) for 90 days after discharge were compared between two groups. The predictive value of sST2 for MACE was evaluated. Results There were significant differences in age, systolic blood pressure, diabetes mellitus, left ventricular ejection fraction (LVEF), cardiac troponin I (cTnI) and N-terminal pro-B type natriuretic peptide (NT-proBNP) between the two groups (all P＜0.05). sST2 was positively correlated with NT-proBNP (r＝0.452, P＝0.001), cTnI (r＝0.298, P＝0.004) and negatively correlated with LVEF (r＝－0.472, P＝0.001). Survival analysis showed that the incidence of MACE in the high sST2 group was higher than that in the low sST2 group, and the cumulative survival rate in the high sST2 group was lower than that in the low sST2 group (P＝0.001). Multivariate Cox regression analysis showed that sST2≥55.0 μg/L was a risk factor for MACE in patients with AMI for 90 days after discharge (hazard ratio 1.4,5%CI 1.025-1.342, P＝0.015). Conclusion Elevated plasma sST2 level implies an increased risk of death and heart failure in patients with AMI.